A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro

Brian M. Wasko, Jacqueline P. Smits, Larry W. Shull, David F. Wiemer, Raymond J. Hohl

Journal of Lipid Research · 2011 · 36 citations · 39 references

DOIFull text

Open access

Concepts

Abstract

Statins and nitrogenous bisphosphonates (NBP) inhibit 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (HMGCR) and farnesyl diphosphate synthase (FDPS), respectively, leading to depletion of farnesyl diphosphate (FPP) and disruption of protein prenylation. Squalene synthase (SQS) utilizes FPP in the first committed step from the mevalonate pathway toward cholesterol biosynthesis. Herein, we have identified novel bisphosphonates as potent and specific inhibitors of SQS, including the tetrasodium salt of 9-biphenyl-4,8-dimethyl-nona-3,7-dienyl-1,1-bisphosphonic acid (compound 5). Compound 5 reduced cholesterol biosynthesis and lead to a substantial intracellular accumulation of FPP without reducing cell viability in HepG2 cells. At high concentrations, lovastatin and zoledronate impaired protein prenylation and decreased cell viability, which limits their potential use for cholesterol depletion. When combined with lovastatin, compound 5 prevented lovastatin-induced FPP depletion and impairment of protein farnesylation. Compound 5 in combination with the NBP zoledronate completely prevented zoledronate-induced impairment of both protein farnesylation and geranylgeranylation. Cotreatment of cells with compound 5 and either lovastatin or zoledronate was able to significantly prevent the reduction of cell viability caused by lovastatin or zoledronate alone. The combination of an SQS inhibitor with an HMGCR or FDPS inhibitor provides a rational approach for reducing cholesterol synthesis while preventing nonsterol isoprenoid depletion. Statins and nitrogenous bisphosphonates (NBP) inhibit 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (HMGCR) and farnesyl diphosphate synthase (FDPS), respectively, leading to depletion of farnesyl diphosphate (FPP) and disruption of protein prenylation. Squalene synthase (SQS) utilizes FPP in the first committed step from the mevalonate pathway toward cholesterol biosynthesis. Herein, we have identified novel bisphosphonates as potent and specific inhibitors of SQS, including the tetrasodium salt of 9-biphenyl-4,8-dimethyl-nona-3,7-dienyl-1,1-bisphosphonic acid (compound 5). Compound 5 reduced cholesterol biosynthesis and lead to a substantial intracellular accumulation of FPP without reducing cell viability in HepG2 cells. At high concentrations, lovastatin and zoledronate impaired protein prenylation and decreased cell viability, which limits their potential use for cholesterol depletion. When combined with lovastatin, compound 5 prevented lovastatin-induced FPP depletion and impairment of protein farnesylation. Compound 5 in combination with the NBP zoledronate completely prevented zoledronate-induced impairment of both protein farnesylation and geranylgeranylation. Cotreatment of cells with compound 5 and either lovastatin or zoledronate was able to significantly prevent the reduction of cell viability caused by lovastatin or zoledronate alone. The combination of an SQS inhibitor with an HMGCR or FDPS inhibitor provides a rational approach for reducing cholesterol synthesis while preventing nonsterol isoprenoid depletion. The mevalonate pathway (Fig. 1) is responsible for production of the core 5-carbon isoprenoid isopentenyl diphosphate (IPP) from 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) (1Goldstein J.L. Brown M.S. Regulation of the mevalonate pathway.Nature. 1990; 343: 425-430Crossref PubMed Scopus (4566) Google Scholar). HMG-CoA is first reduced to mevalonate by HMG-CoA reductase (HMGCR). Through a short series of enzymatic reactions, mevalonate is then converted into IPP. Both IPP and its isomer dimethylallyl diphosphate (DMAPP) are utilized by farnesyl diphosphate synthase (FDPS) to generate the 15-carbon farnesyl diphosphate (FPP), which resides at the major branch point of the mevalonate pathway. Addition of an isoprene unit from IPP to FPP yields geranylgeranyl diphosphate (GGPP), a process mediated by the enzyme geranylgeranyl diphosphate synthase (GGDPS). The isoprene moiety of FPP or GGPP can be posttranslationally adducted onto proteins by protein farnesyltransferase or geranylgeranyltransferases, respectively, in a process collectively referred to as protein prenylation. In the first committed step of de novo cholesterol synthesis, two molecules of FPP are condensed in a head-to-head orientation to first form presqualene diphosphate and subsequently squalene. This reaction is catalyzed by the enzyme squalene synthase (SQS), which is encoded for by the gene farnesyl diphosphate farnesyl transferase 1 (FDFT1). Inhibition of mevalonate pathway targets has yielded multiple drugs with clinical success. Statins (e.g., lovastatin and atorvastatin) are a class of drugs commonly prescribed to reduce cholesterol levels. Statins inhibit HMGCR (2Endo A. Kuroda M. Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity.FEBS Lett. 1976; 72: 323-326Crossref PubMed Scopus (624) Google Scholar), which is the rate-limiting step of cholesterol biosynthesis (3Siperstein M.D. Fagan V.M. Feedback control of mevalonate synthesis by dietary cholesterol.J. Biol. Chem. 1966; 241: 602-609Abstract Full Text PDF PubMed Google Scholar). This leads to upregulation of the low-density lipoprotein (LDL) receptor (LDLR) in the liver and clearance of cholesterol-containing LDL particles from the bloodstream. The use of statin drugs is prevalent because elevated total cholesterol and LDL levels are major risk factors for coronary heart disease (4Wilson P.W. D’Agostino R.B. Levy D. Belanger A.M. Silbershatz H. Kannel W.B. Prediction of coronary heart disease using risk factor categories.Circulation. 1998; 97: 1837-1847Crossref PubMed Scopus (7495) Google Scholar). Although the statins are used abundantly and effectively, there are various reasons for developing novel inhibitors of cholesterol biosynthesis. There can be side effects associated with statin use, such as myopathy and hepatotoxicity (5Armitage J. The safety of statins in clinical practice.Lancet. 2007; 370: 1781-1790Abstract Full Text Full Text PDF PubMed Scopus (674) Google Scholar), which are commonly speculated to be due to the depletion of nonsterol components of the mevalonate pathway (6Bełtowski J. Wójcicka G. Jamroz-Wiśniewska A. Adverse effects of statins - mechanisms and consequences.Curr. Drug Saf. 2009; 4: 209-228Crossref PubMed Scopus (160) Google Scholar). Furthermore, statin use does not always reduce LDL to desired levels (7El Harchaoui K. Akdim F. Stroes E.S. Trip M.D. Kastelein J.J. Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins.Am. J. Cardiovasc. Drugs. 2008; 8: 233-242Crossref PubMed Scopus (24) Google Scholar), which is particularly important as lower LDL target levels are suggested for some patients (8Shepherd J. Barter P. Carmena R. Deedwania P. Fruchart J.C. Haffner S. Hsia J. Breazna A. LaRosa J. Grundy S. et al.Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.Diabetes Care. 2006; 29: 1220-1226Crossref PubMed Scopus (457) Google Scholar, 9Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III).JAMA. 2001; 285: 2486-2497Crossref PubMed Scopus (24461) Google Scholar, 10Javed U. Deedwania P.C. Bhatt D.L. Cannon C.P. Dai D. Hernandez A.F. Peterson E.D. Fonarow G.C. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG).Am. Heart J. 2010; 160 (1136.e1–3): 1130-1136Crossref PubMed Scopus (33) Google Scholar). Inhibition of SQS has attracted much interest as a pharmacological target, and various compounds have been identified as inhibitors (11Seiki S. Frishman W.H. Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia.Cardiol. Rev. 2009; 17: 70-76Crossref PubMed Scopus (41) Google Scholar, 12Elsayed R.K. Evans J.D. Emerging lipid-lowering drugs: squalene synthase inhibitors.Expert Opin. Emerg. Drugs. 2008; 13: 309-322Crossref PubMed Scopus (23) Google Scholar). Lapaquistat (TAK-475, Takeda) progressed to phase III clinical trials, but studies were discontinued after the US Food and Drug Administration recommended suspension of studies with high-dose (100 mg/kg) monotherapy due to hepatotoxicity manifested as elevated levels of liver transaminases (12Elsayed R.K. Evans J.D. Emerging lipid-lowering drugs: squalene synthase inhibitors.Expert Opin. Emerg. Drugs. 2008; 13: 309-322Crossref PubMed Scopus (23) Google Scholar). It is currently unknown whether this was due to an enzyme inhibitory class effect or whether it was specific to the drug. Inhibition of SQS can result in the accumulation of both FPP and FPP metabolites, such as farnesol-derived dicarboxylic acids (13Bostedor R.G. Karkas J.D. Arison B.H. Bansal V.S. Vaidya S. Germershausen J.I. Kurtz M.M. Bergstrom J.D. Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol.J. Biol. Chem. 1997; 272: 9197-9203Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar), which could be responsible for the possible hepatotoxicity with the high-dose monotherapy of lapaquistat. Farnesol itself can be proapoptotic at high concentrations (14Joo J.H. Jetten A.M. Molecular mechanisms involved in farnesol-induced apoptosis.Cancer Lett. 2010; 287: 123-135Crossref PubMed Scopus (145) Google Scholar). Other reported results appeared promising with lapaquistat, with cholesterol levels decreasing in monotherapy treatment. Moreover, the combination therapy of lapaquistat with statins showed additional LDL reduction compared with statins alone (12Elsayed R.K. Evans J.D. Emerging lipid-lowering drugs: squalene synthase inhibitors.Expert Opin. Emerg. Drugs. 2008; 13: 309-322Crossref PubMed Scopus (23) Google Scholar). Also of interest, lapaquistat’s active metabolite T-91485 was capable of preventing statin-induced myotoxicity in a human skeletal muscle cell model (15Nishimoto T. Tozawa R. Amano Y. Wada T. Imura Y. Sugiyama Y. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes.Biochem. Pharmacol. 2003; 66: 2133-2139Crossref PubMed Scopus (72) Google Scholar). Similarly, lapaquistat was able to prevent statin-induced myotoxicity in a guinea pig model (16Nishimoto T. Ishikawa E. Anayama H. Hamajyo H. Nagai H. Hirakata M. Tozawa R. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.Toxicol. Appl. Pharmacol. 2007; 223: 39-45Crossref PubMed Scopus (31) Google Scholar). In addition to the expected cholesterol depletion, other SQS inhibitors have shown the potential for added benefits due to decreased triglyceride biosynthesis (17Hiyoshi H. Yanagimachi M. Ito M. Saeki T. Yoshida I. Okada T. Ikuta H. Shinmyo D. Tanaka K. Kurusu N. et al.Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism.Eur. J. Pharmacol. 2001; 431: 345-352Crossref PubMed Scopus (38) Google Scholar), likely resulting from a farnesol-induced mechanism (18Hiyoshi H. Yanagimachi M. Ito M. Yasuda N. Okada T. Ikuta H. Shinmyo D. Tanaka K. Kurusu N. Yoshida I. et al.Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes.J. Lipid Res. 2003; 44: 128-135Abstract Full Text Full Text PDF PubMed Scopus (48) Google Scholar). Nitrogenous bisphosphonates (NBP; e.g., zoledronate and alendronate) are a second class of clinical drugs targeting the mevalonate pathway, and they are used for treatment of bone-related disorders such as osteoporosis. NBPs function by inhibition of FDPS, thus depleting cellular levels of FPP and other downstream E. E. S. synthase is the target of Res. PubMed Scopus Google Scholar). be as of in which the has been with a This results in and of the Furthermore, the combined with an targeting R. S. A. R.G. into of bisphosphonates on in with 2006; PubMed Scopus Google Scholar). Although compounds have a high for there are of decreased cholesterol levels with patients treated with nitrogenous bisphosphonates E. G. T. of bisphosphonates on Lett. 2008; 29: Google Scholar). the combination of an FDPS inhibitor with an SQS inhibitor has not been various SQS inhibitors are on a C.P. are potent squalene synthase inhibitors and active cholesterol lowering in Biol. Chem. Full Text PDF PubMed Google Scholar), and their for SQS to the prenylation of the mevalonate pathway has not been Herein, we the synthesis and of novel bisphosphonates as potent inhibitors of A is in the of and for novel is on the of a lead compound 5 (Fig. in combination with lovastatin or zoledronate in HepG2 cells. of inhibitors cholesterol biosynthesis while preventing the depletion of nonsterol isoprenoid resulting in reduced cellular effects compared with inhibition of HMGCR or FDPS alone. of compounds 1 K. and of farnesyl as potential inhibitors of farnesyl protein Chem. 1998; PubMed Scopus Google and and of of of Scholar, of on a Chem. Scopus Google has been while compounds were as In acetate was with reported of by and with Chem. Scopus Google (Fig. The was by reaction with and the acetate was of with Chem. Scopus Google Scholar). The resulting then was and in The of was to and of of of Scholar, of on a Chem. Scopus Google Scholar, of farnesol through of by Chem. PubMed Scopus Google with the to the and and of the to the was using the were used without in the of J.H. of acid of farnesyl Scopus Google Scholar). The resulting and were to their and M. The of acid by Lett. Scopus Google Scholar). were in to use for and is in the A human squalene synthase was from The was into and using at using was added to protein protein was using to the were in 5 and were added with enzyme and for at was then added and were for at were by addition of 1 and then 1 was the lower the phase the was to a and was using a was using HepG2 cells were from and at with in 1 and concentrations were by the acid were on or and to was in for after which and were added for 1 at were using and were from and was from were in and to were added for 1 by the addition of 1 of for were using and were using the and A of total and J. PubMed Scopus Google Scholar). were in a of and on was using an of and as the were with to the of a cholesterol to cholesterol were from the and was using a Both FPP and GGPP levels were as reported H. of farnesyl and geranylgeranyl levels in PubMed Scopus Google Scholar). FPP and GGPP were from cells and into by and which were then by on an were to total protein as by The the of enzymes reduce the active cells. It is commonly used as a of cell were to in and were treated with compounds and for by addition of and for an additional and was then and were at was at with a at HepG2 cells were to in and were then with and the cells were in lipoprotein for were then treated for in with was using and with of a step as was from 1 of by using the were from The used was using using an The for at at by of for and for 1 A of compounds was to in inhibitors of A panel of compounds and was for of their inhibitory (Fig. compounds were as in were used to the of compound to inhibit of SQS (compound 1) an of in this Addition of a at the of the (compound to an of The addition of a in an (compound (compound or (compound in of and was used to for in and the were significantly the analysis compounds were from compound but they were not from of compounds for inhibition of of compounds were used to generate are as the in a new of compounds were used to generate are as the inhibitors SQS have potential for effects due to inhibition of other FPP identified and of isoprenoid Chem. 2006; PubMed Scopus Google as an inhibitor of and isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase Chem. 2008; PubMed Scopus (38) Google Scholar). With this in we to whether the compounds active SQS impaired protein farnesylation or can inhibitors of FDPS, or A. and of a series of Chem. 2010; PubMed Scopus (24) Google Scholar, A. by depleting geranylgeranyl Pharmacol. PubMed Scopus Google Scholar). The prenylation of proteins was by for use as of the cellular of protein farnesylation and geranylgeranylation. The utilized in both the and of the of farnesylation on the panel was by the of a The impairment of was by the of a on the used the form of HepG2 cells were treated with lovastatin for as a as this was to both farnesylation and (Fig. mevalonate and the downstream (e.g., FPP and and thus both protein farnesylation and geranylgeranylation. HepG2 cells were treated with of compounds for (compound 1) impaired protein (Fig. Compound impaired compound a impairment was with compounds or Compound 5 was utilized in studies as the lead inhibitor due to its and for Treatment of HepG2 cells with lovastatin for in impairment of both farnesylation of and of impairment of farnesylation was prevented by with lovastatin-induced impairment of was prevented by with GGPP (Fig. Cotreatment of lovastatin with compound 5 prevented lovastatin-induced impairment of but it not completely geranylgeranylation. Treatment of HepG2 cells for with zoledronate caused impairment of farnesylation and (Fig. and with FPP or GGPP prevented the impairment of farnesylation or Cotreatment of HepG2 cells with zoledronate with compound 5 completely prevented both zoledronate-induced impairment of farnesylation and geranylgeranylation. the FPP and GGPP levels from HepG2 cells in to treatment with either compound 5 or lovastatin alone and in combination for In HepG2 cells treated with compound FPP levels were and GGPP levels were compared with control (Fig. 5). lovastatin reduced both FPP and GGPP levels compared with The combination of lovastatin with compound 5 in FPP levels compared with GGPP levels This with the results of lovastatin-induced impairment of but not by with compound at or compound 5 at significantly de novo cholesterol biosynthesis in HepG2 cells compared with HepG2 cells (Fig. The combination of concentrations of lovastatin and compound 5 showed a toward inhibition of cholesterol synthesis compared with but it was not at reduced cholesterol biosynthesis compared with and the combination of compound 5 with zoledronate not significantly cholesterol depletion compared with the at significantly levels compared with control HepG2 cells after (Fig. Compound 5 levels to of but this was not The combination of lovastatin and compound 5 in levels compared with but levels were not elevated cells. at significantly compared with The combination of zoledronate with compound 5 not levels compared with but the levels significantly compared with Treatment of HepG2 cells for with lovastatin significantly reduced compared with control (Fig. Cotreatment with or compound 5 significantly reduction of Compound 5 effect on levels as a treatment. decreased to of control and it was not reduced by FPP (Fig. Cotreatment of HepG2 cells with zoledronate and GGPP or compound 5 significantly reduction of In the we and identified novel inhibitors of A lead inhibitor (compound was identified through in enzyme and not protein prenylation in HepG2 for SQS the prenylation branch of the mevalonate pathway. Other bisphosphonates have been shown to inhibit SQS C.P. are potent squalene synthase inhibitors and active cholesterol lowering in Biol. Chem. Full Text PDF PubMed Google their effects on protein prenylation were not the addition of a at the (compound of for SQS in to (compound The addition of a second in an (compound (compound or (compound SQS as by This the of the is important for It be expected the of compound 5 likely with a Other bisphosphonates have been shown to in this with other proteins Y. R. F. K. S. H. Y. et bisphosphonates as diphosphate synthase an and Chem. 2009; PubMed Scopus Google Scholar). The of the into a of the of has been to with including an inhibitor a J. S. E.S. of human squalene A enzyme in cholesterol Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). and the compound impairment of protein impairment was with the (compound or (compound in to the of in clinical by SQS inhibitors as was on of compound 5 in combination with HMGCR inhibition or FDPS inhibition in HepG2 cells. inhibition of SQS and HMGCR or FDPS provides possible mechanisms for decreasing cholesterol synthesis with disruption of nonsterol isoprenoid levels compared with enzyme due to isoprenoid accumulation or depletion. Treatment of HepG2 cells with compound 5 results in an inhibition of cholesterol biosynthesis and a substantial accumulation of which could result in the of levels of farnesol (14Joo J.H. Jetten A.M. Molecular mechanisms involved in farnesol-induced apoptosis.Cancer Lett. 2010; 287: 123-135Crossref PubMed Scopus (145) Google or farnesol-derived dicarboxylic acids (13Bostedor R.G. Karkas J.D. Arison B.H. Bansal V.S. Vaidya S. Germershausen J.I. Kurtz M.M. Bergstrom J.D. Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol.J. Biol. Chem. 1997; 272: 9197-9203Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar). are for cellular due to their high likely the high concentrations in cell studies could liver targeting and the thus significantly cellular M.D. of and Chem. 2008; PubMed Scopus Google Scholar, H. Yanagimachi M. Ito M. I. Yoshida I. Saeki T. Tanaka H. of a novel squalene synthase inhibitor, on plasma cholesterol in with reductase Lipid Res. Full Text Full Text PDF PubMed Google Scholar, isoprenoid bisphosphonates inhibition of cellular Chem. 2008; PubMed Scopus Google Scholar). With statin there is depletion of mevalonate and downstream components of the mevalonate pathway (2Endo A. Kuroda M. Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity.FEBS Lett. 1976; 72: 323-326Crossref PubMed Scopus (624) Google Scholar). The combination of lovastatin with compound 5 is able to inhibit cholesterol biosynthesis and Furthermore, compound 5 reduction in FPP levels and impairment of protein GGPP levels and protein are not of the effects of statins are to be mediated by GGPP depletion and impairment of protein effects of and clinical J. 2010; PubMed Scopus Google Scholar). statins can and have effects T. in cells to the effect of PubMed Scopus Google Scholar), which are prevented by addition of GGPP but not FPP T. and through inhibition of Pharmacol. Google Scholar). to the GGPP levels and impairment of protein with the combination of compound 5 and lovastatin, some effects be In the combination of compound 5 with lovastatin can prevent reduction in cell results other SQS inhibitors can of statin-induced myopathy (15Nishimoto T. Tozawa R. Amano Y. Wada T. Imura Y. Sugiyama Y. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes.Biochem. Pharmacol. 2003; 66: 2133-2139Crossref PubMed Scopus (72) Google Scholar, T. Ishikawa E. Anayama H. Hamajyo H. Nagai H. Hirakata M. Tozawa R. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.Toxicol. Appl. Pharmacol. 2007; 223: 39-45Crossref PubMed Scopus (31) Google Scholar). effects of the SQS inhibitor lapaquistat as a monotherapy were results a mechanism by which the of SQS inhibitors with statins potential due to treatment with either alone. The FPP accumulation due to SQS inhibition and FPP depletion due to HMGCR inhibition resulting in FPP for other cellular but not in such to It to be a reduction in GGPP levels resulting from this combination of drugs be or With FDPS inhibition by nitrogenous there is decreased and accumulation of the and IPP H. J. J. S. I. production in 2007; PubMed Scopus Google Scholar). nitrogenous IPP accumulation can the of the possible proapoptotic isoprene as H. S. P. M. J. J. A new the and is responsible for the by J. Pharmacol. 2006; PubMed Scopus Google Scholar). With the combination of FDPS and SQS the be first at FDPS, resulting in accumulation of IPP. the through the FDPS inhibition FPP and a second inhibition at SQS, preventing the of squalene and resulting in some accumulation of This FPP accumulation combined with IPP accumulation yields the for GGPP The FPP and could then be utilized in other nonsterol of the mevalonate pathway, such as protein farnesylation and geranylgeranylation. in HepG2 the combination of compound 5 and zoledronate zoledronate-induced impairment of farnesylation and and reduction in In results inhibition of HMGCR and SQS or FDPS and SQS could a of cholesterol reduction with the potential for effects due to decreased depletion of nonsterol compared with HMGCR or FDPS inhibition alone. Treatment using multiple drugs inhibitors combined with statins a possible approach in the or the of novel compounds capable of inhibition could be In and synthesis of a capable of potent FDPS and SQS inhibition is likely to be an and future studies could this The results are from cell and future studies be to in because it is to the effects of targeting in The for with FPP and GGPP levels. The to the of of for with with dimethylallyl diphosphate farnesyl diphosphate farnesyltransferase 1 farnesyl diphosphate synthase farnesyl diphosphate geranylgeranyl diphosphate synthase geranylgeranyl diphosphate HMG-CoA reductase isopentenyl diphosphate LDL receptor nitrogenous squalene synthase

References

39